Centralized repeated resectability assessment of patients with colorectal liver metastases during first-line treatment: prospective study

Abstract Background Metastasectomy is probably underused in metastatic colorectal cancer. The aim of this study was to investigate the effect centralized repeated assessment on resectability rate liver metastases. Methods prospective RAXO a nationwide Finland. Patients with treatable cancer at any site were eligible. This planned substudy included patients baseline metastases between 2012 and 2018. Resectability reassessed by multidisciplinary team Helsinki tertiary referral centre upfront twice during first-line systemic therapy. Outcomes rates, management changes, survival. Results Of 812 included, 301 (37.1 per cent) had liver-only these, tumours categorized as resectable 161 (53.5 cent), became amenable surgery treatment 63 (20.9 cent). Some 207 (68.7 eventually underwent resection or ablation. At baseline, discrepancy central local judgement noted for 102 (33.9 Median disease-free survival (DFS) after first 20 months overall (OS) 79 months. OS diagnosis 80, 32, 21 R0–1 resection, R2/ablation, non-resected groups, 5-year rates 68, 37, 9 cent, respectively. Liver extrahepatic present 511 patients. 72 (14.1 resectable, 53 (10.4 eligible surgery. Eventually 110 (21.5 116 (22.7 DFS from 7 median 55 79, 42, 17 65, 39, 2 Conclusion Repeated improved rates.